One CRO or multiple partners? Why the single-CRO model is increasingly winning in clinical trials
Choosing the CRO collaboration model is one of the most important strategic decisions a sponsor makes before starting a clinical trial. In practice, there are two main approaches: working with a single, full-service CRO (the single-CRO model) or dividing responsibilities among several specialized vendors. While both options have their place, more and more sponsors are opting for a single-CRO model due to greater operational efficiency and lower project risk.
The biggest advantage of working with one CRO is consistent project management. Clinical trials require continuous coordination across regulatory activities, clinical operations, data management, biostatistics, pharmacovigilance/medical device safety, and communication with research sites. When all these areas are handled by a single partner, information flows faster and decisions are made based on a complete view of the project. This eliminates the risk of inconsistent protocol interpretation or fragmented responsibility across multiple vendors.
A multi-CRO model may seem attractive at the planning stage—especially when sponsors aim to leverage highly specialized services from different providers. In practice, however, it often leads to increased project complexity. Each additional vendor introduces separate communication processes, different working standards, independent reporting systems, and the need for extra oversight from the sponsor. As a result, the sponsor effectively becomes the project integrator, significantly increasing team workload and the risk of delays.
A single CRO, on the other hand, provides one central point of accountability. The sponsor works with one partner responsible for timelines, data quality, and coordination, which simplifies communication and shortens decision-making paths. This is particularly important at critical stages of a study, such as responding to regulatory queries, implementing protocol amendments, or addressing recruitment challenges that require rapid operational action.
Another key benefit of the single-CRO model is greater quality consistency. A unified SOP system, standardized monitoring practices, shared data management tools, and harmonized reporting reduce the risk of errors resulting from procedural differences between vendors. In practice, this translates into higher-quality documentation and better readiness for audits and regulatory inspections.
The financial aspect is also important. While working with multiple CROs may appear to optimize costs for individual services, it often generates additional coordination expenses, prolongs the start-up phase, and increases the risk of scope changes. A single CRO partner can offer a more predictable budget management model and better control over the total project cost.
Of course, there are cases where a multi-vendor model may be justified—for example, in large global research programs or highly specialized technological services. However, in most clinical trials and real-world evidence (RWE) projects, the single-CRO model proves to be more efficient, stable, and operationally secure.
Biostat supports sponsors as a full-service CRO partner, integrating regulatory, operational, and analytical activities within a single project team. This approach simplifies study management, increases timeline predictability, and allows sponsors to focus on strategic product development goals.
If you are considering the optimal collaboration model for your upcoming study, it is worth evaluating not only the scope of services but also how the project will be managed. In many cases, choosing the right single CRO means fewer risks, faster execution, and greater control over the entire clinical trial.
